Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

The biotech startup, a spinout of the University of Colorado Anschutz Medical Campus, launched this year with $15 million in ...

The firm submitted data showing that more than 70 percent of patients with HER2-mutated NSCLC who hadn't received anti-HER2 therapy responded to sevabertinib.

The approval was based on results from the Phase II HORIZON-Lung trial, in which the treatment had a median progression-free survival of 11.5 months.

The firm will study AKY-1189 in Nectin-4-expressing tumors, including urothelial and triple-negative breast cancer.

Taysha expects to initiate the pivotal study, which will be part B of an ongoing Phase I/II trial, of TSHA-102 in the third quarter.